{{Rsnum
|rsid=28757184
|Gene=CYP19A1
|Chromosome=15
|position=51222375
|Orientation=plus
|ReferenceAllele=C
|MissenseAllele=T
|GMAF=0.02617
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP19A1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 91.2 | 8.8 | 0.0
| HCB | 99.3 | 0.7 | 0.0
| JPT | 0.0 | 0.0 | 0.0
| YRI | 89.1 | 10.2 | 0.7
| ASW | 92.9 | 7.1 | 0.0
| CHB | 99.3 | 0.7 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 92.7 | 7.3 | 0.0
| MEX | 94.7 | 5.3 | 0.0
| MKK | 85.9 | 13.5 | 0.6
| TSI | 90.2 | 8.8 | 1.0
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19470632
|Title=In vitro kinetic properties of the Thr201Met variant of human aromatase gene CYP19A1: Functional responses to substrate and product inhibition and enzyme inhibitors
}}

{{PMID Auto
|PMID=18941913
|Title=Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer.
|OA=1
}}

{{PMID Auto
|PMID=19015200
|Title=Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.
|OA=1
}}

{{PMID Auto
|PMID=20144226
|Title=A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
|OA=1
}}

{{GET Evidence
|gene=CYP19A1
|aa_change=Thr201Met
|aa_change_short=T201M
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs28757184
|overall_frequency_n=468
|overall_frequency_d=10758
|overall_frequency=0.0435025
|n_genomes=5
|n_genomes_annotated=0
|n_haplomes=5
|n_articles=0
|n_articles_annotated=0
|gene_in_genetests=Y
|pph2_score=0.002
|genetests_testable=Y
|nblosum100=2
|autoscore=2
|n_web_uneval=10
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}